猴先天性巨细胞病毒(CMV)传播模型对原发恒河巨细胞病毒(CMV)感染的浆母细胞应答

Q2 Biochemistry, Genetics and Molecular Biology
Clinical and Vaccine Immunology Pub Date : 2017-05-05 Print Date: 2017-05-01 DOI:10.1128/CVI.00510-16
Qihua Fan, Cody S Nelson, Kristy M Bialas, Flavia Chiuppesi, Joshua Amos, Thaddeus C Gurley, Dawn Jones Marshall, Joshua Eudailey, Holly Heimsath, Jonathon Himes, Ashlesha Deshpande, Mark R Walter, Felix Wussow, Don J Diamond, Peter A Barry, M Anthony Moody, Amitinder Kaur, Sallie R Permar
{"title":"猴先天性巨细胞病毒(CMV)传播模型对原发恒河巨细胞病毒(CMV)感染的浆母细胞应答","authors":"Qihua Fan,&nbsp;Cody S Nelson,&nbsp;Kristy M Bialas,&nbsp;Flavia Chiuppesi,&nbsp;Joshua Amos,&nbsp;Thaddeus C Gurley,&nbsp;Dawn Jones Marshall,&nbsp;Joshua Eudailey,&nbsp;Holly Heimsath,&nbsp;Jonathon Himes,&nbsp;Ashlesha Deshpande,&nbsp;Mark R Walter,&nbsp;Felix Wussow,&nbsp;Don J Diamond,&nbsp;Peter A Barry,&nbsp;M Anthony Moody,&nbsp;Amitinder Kaur,&nbsp;Sallie R Permar","doi":"10.1128/CVI.00510-16","DOIUrl":null,"url":null,"abstract":"<p><p>Human cytomegalovirus (HCMV) is the most common congenital infection worldwide and the leading infectious cause of neurologic deficits and hearing loss in newborns. Development of a maternal HCMV vaccine to prevent vertical virus transmission is a high priority, yet protective maternal immune responses following acute infection are poorly understood. To characterize the maternal humoral immune response to primary CMV infection, we investigated the plasmablast and early antibody repertoire using a nonhuman primate model with two acutely rhesus CMV (RhCMV)-infected animals-a CD4<sup>+</sup> T cell-depleted dam that experienced fetal loss shortly after vertical RhCMV transmission and an immunocompetent dam that did not transmit RhCMV to her infant. Compared to the CD4<sup>+</sup> T cell-depleted dam that experienced fetal loss, the immunocompetent, nontransmitting dam had a more rapid and robust plasmablast response that produced a high proportion of RhCMV-reactive antibodies, including the first identified monoclonal antibody specific for soluble and membrane-associated RhCMV envelope glycoprotein B (gB). Additionally, we noted that plasmablast RhCMV-specific antibodies had variable gene usage and maturation similar to those observed in a monkey chronically coinfected with simian immunodeficiency virus (SIV) and RhCMV. This study reveals characteristics of the early maternal RhCMV-specific humoral immune responses to primary RhCMV infection in rhesus monkeys and may contribute to a future understanding of what antibody responses should be targeted by a vaccine to eliminate congenital HCMV transmission. Furthermore, the identification of an RhCMV gB-specific monoclonal antibody underscores the possibility of modeling future HCMV vaccine strategies in this nonhuman primate model.</p>","PeriodicalId":10271,"journal":{"name":"Clinical and Vaccine Immunology","volume":"24 5","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2017-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1128/CVI.00510-16","citationCount":"10","resultStr":"{\"title\":\"Plasmablast Response to Primary Rhesus Cytomegalovirus (CMV) Infection in a Monkey Model of Congenital CMV Transmission.\",\"authors\":\"Qihua Fan,&nbsp;Cody S Nelson,&nbsp;Kristy M Bialas,&nbsp;Flavia Chiuppesi,&nbsp;Joshua Amos,&nbsp;Thaddeus C Gurley,&nbsp;Dawn Jones Marshall,&nbsp;Joshua Eudailey,&nbsp;Holly Heimsath,&nbsp;Jonathon Himes,&nbsp;Ashlesha Deshpande,&nbsp;Mark R Walter,&nbsp;Felix Wussow,&nbsp;Don J Diamond,&nbsp;Peter A Barry,&nbsp;M Anthony Moody,&nbsp;Amitinder Kaur,&nbsp;Sallie R Permar\",\"doi\":\"10.1128/CVI.00510-16\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Human cytomegalovirus (HCMV) is the most common congenital infection worldwide and the leading infectious cause of neurologic deficits and hearing loss in newborns. Development of a maternal HCMV vaccine to prevent vertical virus transmission is a high priority, yet protective maternal immune responses following acute infection are poorly understood. To characterize the maternal humoral immune response to primary CMV infection, we investigated the plasmablast and early antibody repertoire using a nonhuman primate model with two acutely rhesus CMV (RhCMV)-infected animals-a CD4<sup>+</sup> T cell-depleted dam that experienced fetal loss shortly after vertical RhCMV transmission and an immunocompetent dam that did not transmit RhCMV to her infant. Compared to the CD4<sup>+</sup> T cell-depleted dam that experienced fetal loss, the immunocompetent, nontransmitting dam had a more rapid and robust plasmablast response that produced a high proportion of RhCMV-reactive antibodies, including the first identified monoclonal antibody specific for soluble and membrane-associated RhCMV envelope glycoprotein B (gB). Additionally, we noted that plasmablast RhCMV-specific antibodies had variable gene usage and maturation similar to those observed in a monkey chronically coinfected with simian immunodeficiency virus (SIV) and RhCMV. This study reveals characteristics of the early maternal RhCMV-specific humoral immune responses to primary RhCMV infection in rhesus monkeys and may contribute to a future understanding of what antibody responses should be targeted by a vaccine to eliminate congenital HCMV transmission. Furthermore, the identification of an RhCMV gB-specific monoclonal antibody underscores the possibility of modeling future HCMV vaccine strategies in this nonhuman primate model.</p>\",\"PeriodicalId\":10271,\"journal\":{\"name\":\"Clinical and Vaccine Immunology\",\"volume\":\"24 5\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-05-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1128/CVI.00510-16\",\"citationCount\":\"10\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical and Vaccine Immunology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1128/CVI.00510-16\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2017/5/1 0:00:00\",\"PubModel\":\"Print\",\"JCR\":\"Q2\",\"JCRName\":\"Biochemistry, Genetics and Molecular Biology\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Vaccine Immunology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1128/CVI.00510-16","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2017/5/1 0:00:00","PubModel":"Print","JCR":"Q2","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}
引用次数: 10

摘要

人类巨细胞病毒(HCMV)是世界上最常见的先天性感染,也是新生儿神经功能缺损和听力损失的主要感染性原因。开发母体HCMV疫苗以预防垂直病毒传播是一个高度优先事项,但对急性感染后母体保护性免疫反应了解甚少。为了描述母体对原发性巨细胞病毒感染的体液免疫反应,我们使用一个非人灵长类动物模型研究了血浆母细胞和早期抗体库,该模型有两只急性恒河巨细胞病毒(RhCMV)感染动物——一个CD4+ T细胞耗尽的大坝在垂直传播RhCMV后不久经历了胎儿丢失,另一个免疫正常的大坝没有将RhCMV传播给她的婴儿。与经历胎儿丢失的CD4+ T细胞耗尽的大坝相比,免疫能力强、不传递的大坝具有更快速和更强大的浆母细胞反应,产生高比例的RhCMV反应性抗体,包括首次鉴定的针对可溶性和膜相关RhCMV包膜糖蛋白B (gB)的单克隆抗体。此外,我们注意到浆母细胞RhCMV特异性抗体具有可变的基因使用和成熟,这与在猴免疫缺陷病毒(SIV)和RhCMV慢性共感染的猴子中观察到的相似。这项研究揭示了恒河猴对原发性RhCMV感染的早期母体RhCMV特异性体液免疫反应的特征,并可能有助于未来了解疫苗应该针对哪些抗体反应来消除先天性HCMV传播。此外,RhCMV gb特异性单克隆抗体的鉴定强调了在这种非人灵长类动物模型中建模未来HCMV疫苗策略的可能性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Plasmablast Response to Primary Rhesus Cytomegalovirus (CMV) Infection in a Monkey Model of Congenital CMV Transmission.

Plasmablast Response to Primary Rhesus Cytomegalovirus (CMV) Infection in a Monkey Model of Congenital CMV Transmission.

Plasmablast Response to Primary Rhesus Cytomegalovirus (CMV) Infection in a Monkey Model of Congenital CMV Transmission.

Plasmablast Response to Primary Rhesus Cytomegalovirus (CMV) Infection in a Monkey Model of Congenital CMV Transmission.

Human cytomegalovirus (HCMV) is the most common congenital infection worldwide and the leading infectious cause of neurologic deficits and hearing loss in newborns. Development of a maternal HCMV vaccine to prevent vertical virus transmission is a high priority, yet protective maternal immune responses following acute infection are poorly understood. To characterize the maternal humoral immune response to primary CMV infection, we investigated the plasmablast and early antibody repertoire using a nonhuman primate model with two acutely rhesus CMV (RhCMV)-infected animals-a CD4+ T cell-depleted dam that experienced fetal loss shortly after vertical RhCMV transmission and an immunocompetent dam that did not transmit RhCMV to her infant. Compared to the CD4+ T cell-depleted dam that experienced fetal loss, the immunocompetent, nontransmitting dam had a more rapid and robust plasmablast response that produced a high proportion of RhCMV-reactive antibodies, including the first identified monoclonal antibody specific for soluble and membrane-associated RhCMV envelope glycoprotein B (gB). Additionally, we noted that plasmablast RhCMV-specific antibodies had variable gene usage and maturation similar to those observed in a monkey chronically coinfected with simian immunodeficiency virus (SIV) and RhCMV. This study reveals characteristics of the early maternal RhCMV-specific humoral immune responses to primary RhCMV infection in rhesus monkeys and may contribute to a future understanding of what antibody responses should be targeted by a vaccine to eliminate congenital HCMV transmission. Furthermore, the identification of an RhCMV gB-specific monoclonal antibody underscores the possibility of modeling future HCMV vaccine strategies in this nonhuman primate model.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Clinical and Vaccine Immunology
Clinical and Vaccine Immunology 医学-传染病学
CiteScore
2.88
自引率
0.00%
发文量
0
审稿时长
1.5 months
期刊介绍: Cessation. First launched as Clinical and Diagnostic Laboratory Immunology (CDLI) in 1994, CVI published articles that enhanced the understanding of the immune response in health and disease and after vaccination by showcasing discoveries in clinical, laboratory, and vaccine immunology. CVI was committed to advancing all aspects of vaccine research and immunization, including discovery of new vaccine antigens and vaccine design, development and evaluation of vaccines in animal models and in humans, characterization of immune responses and mechanisms of vaccine action, controlled challenge studies to assess vaccine efficacy, study of vaccine vectors, adjuvants, and immunomodulators, immune correlates of protection, and clinical trials.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信